Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 105Neoplasms 11Neoplasm Metastasis 11Glioma 8Ovarian Neoplasms 6Melanoma 6Glioblastoma 6Squamous Cell Carcinoma of Head and Neck 5Liposarcoma 5Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Recurrence 4Medulloblastoma 4Endometrial Neoplasms 4Diffuse Intrinsic Pontine Glioma 4Colorectal Neoplasms 4Breast Diseases 4Brain Neoplasms 4Neuroblastoma 3Neoplasms by Site 3Lymphoma 3Hereditary Sensory and Autonomic Neuropathies 3Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Astrocytoma 3Triple Negative Breast Neoplasms 2Rhabdoid Tumor 2Prostatic Neoplasms 2Neoplasms, Germ Cell and Embryonal 2

Interventions

niraparib 3Paclitaxel 2Letrozole 2trametinib 1ribociclib 1pembrolizumab 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1CTLA-4 Antigen 1Blood Specimen Collection 1Axitinib 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cystadenocarcinoma, Serous × ribociclib × Clear all
NCT03673124 2025-12-23

Ribociclib and Letrozole Treatment in Ovarian Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled 19 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡